Skip to main content
Log in

Canadian MS patients gain access to interferon-β-1a and teriflunomide

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. EMD Serono. Ontario Reimburses CIS Indication for REBIF(Rm), a First-Line Treatment for Multiple Sclerosis. Media Release : 25 May 2015. Available from: URL: http://www.emdserono.ca

  2. Sanofi. Prince Edward Island funds treatment with AUBAGIO(Tm) for Relapsing Remitting Multiple Sclerosis. Media Release : 25 May 2015. Available from: URL: http://www.sanofi.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Canadian MS patients gain access to interferon-β-1a and teriflunomide. PharmacoEcon Outcomes News 729, 33 (2015). https://doi.org/10.1007/s40274-015-2190-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2190-y

Navigation